Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lundbeck Breaks Into MAb Development, Adds To Suite Of Parkinson's Candidates

Executive Summary

Denmark's mid-sized biopharma, Lundbeck, has taken another potential Parkinson's disease therapeutic into early clinical studies, the third this year, and this time it's a monoclonal antibody, not a small molecule.

You may also be interested in...



AbbVie Validates Voyager’s One-Shot Approach With Parkinson’s Collaboration

AbbVie and existing partner Voyager Therapeutics are attempting to cross the blood-brain barrier with a new collaboration on vectorized antibodies to treat Parkinson’s disease and other synucleinopathies such as Lewy body dementia and multiple system atrophy.

Lundbeck Launches Rexulti In Europe, Phase II LU AF11167 Trial In Schizophrenia

Danish CNS specialist begins Rexulti roll-out in Europe and proof-of-concept study of its early pipeline candidate Lu AF11167.

1ST Bio Bets On BBB-Penetrating C-ABL Inhibitor As Potential Disease-Modifying Parkinson's Drug

Emerging Company Profile: 1ST Biotherapeutics CEO highlights its lead candidate program – a novel small molecule c-Abl inhibitor, which touts superior blood-brain penetration and selectivity – for its potential to become a disease-modifying drug for Parkinson's disease.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel